Nifty
Sensex
:
:
11967.70
40767.14
70.90 (0.60%)
222.77 (0.55%)

Pharmaceuticals & Drugs - Global

Rating :
79/99

BSE: 524804 | NSE: AUROPHARMA

800.30
20-Oct-2020
  • Open
  • High
  • Low
  • Previous Close
  •  799.50
  •  812.60
  •  795.50
  •  800.60
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2048537
  •  16453.18
  •  967.50
  •  288.85

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 46,886.81
  • 15.76
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 49,606.63
  • 0.37%
  • 2.66

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 52.01%
  • 0.95%
  • 9.66%
  • FII
  • DII
  • Others
  • 23.01%
  • 13.60%
  • 0.77%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.09
  • 10.86
  • 11.95

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.58
  • 8.82
  • 5.22

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.58
  • 7.06
  • 5.55

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.70
  • 17.11
  • 15.54

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.19
  • 3.94
  • 2.87

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.00
  • 11.79
  • 10.31

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
5,924.78
5,444.60
8.82%
6,158.43
5,292.20
16.37%
5,895.00
5,269.67
11.87%
5,600.47
4,751.40
17.87%
Expenses
4,667.43
4,298.20
8.59%
4,842.21
4,234.73
14.35%
4,686.96
4,183.29
12.04%
4,460.25
3,765.13
18.46%
EBITDA
1,257.35
1,146.40
9.68%
1,316.22
1,057.47
24.47%
1,208.04
1,086.38
11.20%
1,140.22
986.27
15.61%
EBIDTM
21.22%
21.06%
14.01%
19.98%
20.49%
20.62%
20.36%
20.76%
Other Income
115.59
15.78
632.51%
32.59
32.27
0.99%
30.93
63.85
-51.56%
20.62
26.26
-21.48%
Interest
21.07
49.89
-57.77%
31.83
50.08
-36.44%
37.11
47.65
-22.12%
40.94
35.39
15.68%
Depreciation
255.52
240.86
6.09%
232.41
186.62
24.54%
250.13
163.12
53.34%
243.31
163.68
48.65%
PBT
1,096.35
858.73
27.67%
1,096.82
816.86
34.27%
938.81
914.42
2.67%
863.83
786.62
9.82%
Tax
303.67
227.76
33.33%
228.52
231.12
-1.12%
232.86
204.78
13.71%
224.37
175.42
27.90%
PAT
792.68
630.97
25.63%
868.30
585.74
48.24%
705.95
709.64
-0.52%
639.46
611.20
4.62%
PATM
13.38%
11.59%
7.11%
11.07%
11.98%
13.47%
11.42%
12.86%
EPS
13.53
10.77
25.63%
14.82
10.00
48.20%
12.05
12.11
-0.50%
10.91
10.43
4.60%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
23,578.68
23,098.51
19,563.55
16,463.03
14,909.54
13,794.65
12,120.52
8,099.79
5,855.32
4,627.40
4,381.48
Net Sales Growth
13.59%
18.07%
18.83%
10.42%
8.08%
13.81%
49.64%
38.33%
26.54%
5.61%
 
Cost Of Goods Sold
11,984.82
8,720.74
7,886.32
6,085.55
5,911.00
5,612.30
5,099.89
3,275.54
2,730.00
2,303.99
1,963.83
Gross Profit
11,593.86
14,377.77
11,677.23
10,377.48
8,998.54
8,182.35
7,020.63
4,824.25
3,125.32
2,323.41
2,417.65
GP Margin
49.17%
62.25%
59.69%
63.04%
60.35%
59.32%
57.92%
59.56%
53.38%
50.21%
55.18%
Total Expenditure
18,656.85
18,234.20
15,611.61
12,691.28
11,475.26
10,606.53
9,556.90
5,966.14
4,994.37
4,066.10
3,418.22
Power & Fuel Cost
-
587.68
556.79
470.95
437.14
419.26
359.60
349.84
324.72
232.36
208.26
% Of Sales
-
2.54%
2.85%
2.86%
2.93%
3.04%
2.97%
4.32%
5.55%
5.02%
4.75%
Employee Cost
-
3,219.18
2,584.87
2,130.84
1,767.76
1,542.62
1,302.26
802.43
663.31
535.69
425.07
% Of Sales
-
13.94%
13.21%
12.94%
11.86%
11.18%
10.74%
9.91%
11.33%
11.58%
9.70%
Manufacturing Exp.
-
2,331.41
2,037.95
1,611.12
1,309.64
1,256.18
1,022.70
772.04
623.04
543.16
511.60
% Of Sales
-
10.09%
10.42%
9.79%
8.78%
9.11%
8.44%
9.53%
10.64%
11.74%
11.68%
General & Admin Exp.
-
1,320.69
1,006.68
1,068.22
997.32
686.38
666.38
283.49
197.83
130.74
120.34
% Of Sales
-
5.72%
5.15%
6.49%
6.69%
4.98%
5.50%
3.50%
3.38%
2.83%
2.75%
Selling & Distn. Exp.
-
1,524.75
1,122.67
1,025.85
848.43
901.87
878.98
359.60
305.98
208.20
141.59
% Of Sales
-
6.60%
5.74%
6.23%
5.69%
6.54%
7.25%
4.44%
5.23%
4.50%
3.23%
Miscellaneous Exp.
-
529.75
416.33
298.75
203.97
187.92
227.09
123.20
149.49
111.96
141.59
% Of Sales
-
2.29%
2.13%
1.81%
1.37%
1.36%
1.87%
1.52%
2.55%
2.42%
1.08%
EBITDA
4,921.83
4,864.31
3,951.94
3,771.75
3,434.28
3,188.12
2,563.62
2,133.65
860.95
561.30
963.26
EBITDA Margin
20.87%
21.06%
20.20%
22.91%
23.03%
23.11%
21.15%
26.34%
14.70%
12.13%
21.98%
Other Income
199.73
191.87
155.32
101.98
115.89
203.80
96.71
21.56
28.54
24.70
71.41
Interest
130.95
305.13
262.60
77.72
66.72
256.70
159.87
310.16
266.64
277.24
64.65
Depreciation
981.37
966.71
667.95
557.97
427.63
392.37
332.61
312.53
248.74
200.53
171.50
PBT
3,995.81
3,784.34
3,176.71
3,238.04
3,055.82
2,742.85
2,167.85
1,532.52
374.11
108.23
798.52
Tax
989.42
913.52
726.85
818.27
759.65
720.71
596.59
363.45
82.71
-88.81
225.12
Tax Rate
24.76%
24.31%
23.53%
25.27%
24.86%
26.28%
27.52%
23.72%
22.11%
41.70%
28.56%
PAT
3,006.39
2,846.14
2,362.03
2,420.03
2,296.64
2,023.64
1,575.77
1,172.85
293.86
-123.50
563.45
PAT before Minority Interest
3,006.76
2,844.69
2,361.80
2,419.77
2,296.17
2,022.14
1,571.26
1,169.07
291.40
-124.14
563.06
Minority Interest
0.37
1.45
0.23
0.26
0.47
1.50
4.51
3.78
2.46
0.64
0.39
PAT Margin
12.75%
12.32%
12.07%
14.70%
15.40%
14.67%
13.00%
14.48%
5.02%
-2.67%
12.86%
PAT Growth
18.48%
20.50%
-2.40%
5.37%
13.49%
28.42%
34.35%
299.12%
-
-
 
EPS
51.31
48.58
40.31
41.30
39.20
34.54
26.89
20.02
5.02
-2.11
9.62

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
16,810.38
13,890.78
11,680.42
9,371.91
7,287.30
5,155.91
3,750.15
2,605.76
2,339.65
2,444.83
Share Capital
58.59
58.59
58.59
58.59
58.52
29.20
29.15
29.12
29.11
29.11
Total Reserves
16,751.79
13,832.13
11,621.76
9,313.22
7,227.50
5,126.71
3,721.00
2,576.64
2,310.54
2,415.72
Non-Current Liabilities
565.88
335.81
594.11
102.07
583.85
1,591.60
1,493.91
1,225.26
967.29
645.49
Secured Loans
0.00
179.95
451.20
177.59
380.10
773.54
1,101.31
1,084.11
862.08
449.74
Unsecured Loans
0.00
0.00
0.00
3.81
362.71
587.93
178.05
64.15
102.55
73.61
Long Term Provisions
74.71
46.54
55.86
39.13
23.36
24.35
9.18
9.00
4.24
3.09
Current Liabilities
11,386.75
12,042.90
8,665.89
6,605.60
7,840.22
6,136.40
4,220.04
3,430.83
2,915.05
2,768.49
Trade Payables
2,545.01
2,677.13
2,372.90
2,154.70
2,457.03
2,051.13
1,351.20
963.75
660.14
776.35
Other Current Liabilities
2,874.56
2,545.41
1,967.42
1,286.82
1,577.58
1,364.95
387.68
150.87
580.34
699.09
Short Term Borrowings
5,422.30
6,573.21
4,031.34
2,902.72
3,672.68
2,502.08
2,354.56
2,236.12
1,608.21
1,234.73
Short Term Provisions
544.88
247.15
294.23
261.36
132.93
218.24
126.60
80.09
66.36
58.32
Total Liabilities
28,763.15
26,271.08
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93
Net Block
9,396.47
8,474.85
6,520.68
4,833.78
4,179.69
3,705.64
2,721.67
2,638.87
2,194.65
1,738.60
Gross Block
12,441.26
10,497.62
7,894.78
5,635.49
4,569.83
5,446.13
4,182.96
3,763.47
3,086.25
2,438.00
Accumulated Depreciation
3,044.79
2,022.77
1,374.10
801.71
390.14
1,740.49
1,461.29
1,124.60
891.60
699.40
Non Current Assets
12,350.65
10,906.57
8,764.08
6,875.48
5,419.57
4,610.93
3,858.59
3,136.10
2,968.16
2,546.75
Capital Work in Progress
1,985.94
1,668.46
1,583.04
1,458.08
848.14
370.35
256.67
167.82
515.74
582.86
Non Current Investment
554.69
360.20
311.52
245.85
122.94
0.14
19.76
22.24
19.86
38.49
Long Term Loans & Adv.
376.94
364.44
261.91
256.48
236.56
455.27
789.04
237.82
108.12
110.77
Other Non Current Assets
36.61
38.62
86.93
81.29
32.24
30.25
18.40
18.66
0.12
1.47
Current Assets
16,412.50
15,364.51
12,178.16
9,206.18
10,294.35
8,298.80
5,631.18
4,136.75
3,264.04
3,321.18
Current Investments
0.02
0.02
0.02
0.02
0.02
19.65
0.03
0.04
18.68
0.04
Inventories
7,699.87
7,245.60
5,858.41
4,330.54
4,056.14
3,611.30
2,367.54
1,923.59
1,545.56
1,455.27
Sundry Debtors
4,315.15
3,413.78
3,080.20
2,765.33
4,606.68
3,539.17
2,636.57
1,596.98
1,239.96
1,230.98
Cash & Bank
2,842.15
1,957.18
1,262.25
513.48
800.26
469.11
178.58
208.45
70.86
186.72
Other Current Assets
1,555.31
1,919.82
1,223.32
1,084.72
831.25
659.57
448.46
407.69
388.98
448.17
Short Term Loans & Adv.
1,065.96
828.11
753.96
512.09
366.88
387.90
237.22
207.51
216.67
358.87
Net Current Assets
5,025.75
3,321.61
3,512.27
2,600.58
2,454.13
2,162.40
1,411.14
705.92
348.99
552.69
Total Assets
28,763.15
26,271.08
20,942.24
16,081.66
15,713.92
12,909.73
9,489.77
7,272.85
6,232.20
5,867.93

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
4,381.28
1,622.03
1,954.52
3,278.58
1,419.76
1,236.81
646.28
274.87
326.25
335.11
PBT
3,743.04
3,091.35
3,241.18
3,060.84
2,744.30
2,167.85
1,532.52
374.11
108.23
798.52
Adjustment
1,091.17
810.77
535.02
408.92
487.50
406.28
515.12
441.54
387.22
197.72
Changes in Working Capital
276.87
-1,510.26
-1,123.12
582.52
-1,079.41
-841.73
-1,057.41
-421.56
-128.34
-469.45
Cash after chg. in Working capital
5,111.08
2,391.86
2,653.08
4,052.28
2,152.39
1,732.40
990.23
394.09
367.11
526.79
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-729.80
-769.83
-698.56
-773.70
-732.63
-495.59
-343.95
-119.22
-40.86
-191.68
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-1,567.64
-2,876.83
-1,926.59
-1,787.04
-1,445.21
-1,397.97
-818.74
-246.34
-563.16
-599.07
Net Fixed Assets
-606.64
-799.00
-771.00
-1,092.24
125.11
-533.87
-141.02
-224.46
-376.05
-396.28
Net Investments
-180.64
-371.56
-285.55
-498.60
-170.60
-140.13
-164.64
-78.98
-135.92
-122.17
Others
-780.36
-1,706.27
-870.04
-196.20
-1,399.72
-723.97
-513.08
57.10
-51.19
-80.62
Cash from Financing Activity
-1,947.18
1,919.06
864.15
-1,915.26
365.44
93.21
117.64
108.09
118.85
406.98
Net Cash Inflow / Outflow
866.46
664.26
892.08
-423.72
339.99
-67.95
-54.82
136.62
-118.06
143.02
Opening Cash & Equivalents
1,875.58
1,209.94
318.03
743.49
403.81
148.02
202.73
65.64
183.71
44.72
Closing Cash & Equivalent
2,746.82
1,875.58
1,209.94
319.63
743.50
461.10
148.02
202.73
65.64
183.71

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
286.92
237.08
199.36
159.96
124.50
88.29
64.33
44.74
40.19
41.99
ROA
10.34%
10.00%
13.07%
14.44%
14.13%
14.03%
13.95%
4.32%
-2.05%
10.57%
ROE
18.53%
18.47%
22.99%
27.57%
32.51%
35.29%
36.79%
11.78%
-5.19%
26.35%
ROCE
18.80%
17.97%
22.72%
24.92%
27.35%
27.18%
27.18%
11.17%
1.25%
19.29%
Fixed Asset Turnover
4.12
2.13
2.44
2.96
2.79
2.55
2.08
1.75
1.71
1.85
Receivable days
29.85
60.58
64.66
89.16
106.53
91.84
93.55
86.28
95.44
89.07
Inventory Days
57.72
122.24
112.70
101.43
100.27
88.91
94.82
105.51
115.91
104.17
Payable days
52.98
60.06
67.77
75.73
81.50
67.49
71.06
57.79
64.70
70.79
Cash Conversion Cycle
34.59
122.76
109.58
114.86
125.30
113.25
117.31
134.00
146.65
122.45
Total Debt/Equity
0.33
0.50
0.41
0.36
0.69
0.86
1.01
1.32
1.32
0.99
Interest Cover
13.32
12.76
42.66
46.80
11.69
14.56
5.94
2.40
0.23
13.19

News Update:


  • Aurobindo Pharma to acquire entire stake in MViyeS
    19th Oct 2020, 11:59 AM

    MViyeS is holding 32.18% shareholding in Eugia Pharma Specialities, a joint venture company in which the Company is holding 67.82%

    Read More
  • Aurobindo Pharma collaborates with CSIR to develop COVID-19 vaccine
    16th Sep 2020, 08:50 AM

    Aurobindo will undertake clinical development and commercialization of the vaccines

    Read More
  • DBT- BIRAC supports Aurobindo Pharma’s COVID-19 vaccine development
    15th Sep 2020, 16:34 PM

    Government of India has facilitated the establishment of the r-VSV vaccine manufacturing platform for the first time in India

    Read More
  • Aurobindo Pharma reports 23% rise in Q1 consolidated net profit
    13th Aug 2020, 11:56 AM

    Total consolidated income of the company increased by 10.62% at Rs 6,040.37 crore for Q1FY21

    Read More
  • Aurobindo Pharma - Quarterly Results
    12th Aug 2020, 19:39 PM

    Read More
  • Aurobindo Pharma working on developing several viral vaccines including one for COVID-19
    7th Aug 2020, 13:22 PM

    During the year (FY20), the company has further strengthened its presence in the vaccines segment through the acquisition of R&D assets from Profectus Biosciences through Auro Vaccines

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.